Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer by Lammers, PE et al.
ARTICLE
Clinical Study
Neoadjuvant PF-05280014 (a potential trastuzumab
biosimilar) versus trastuzumab for operable HER2+
breast cancer
Philip E. Lammers1, Magdolna Dank2, Riccardo Masetti3, Richat Abbas4, Fiona Hilton5, Jennifer Coppola6 and Ira Jacobs6
BACKGROUND: This randomised, double-blind study compared pharmacokinetics, efficacy, safety and immunogenicity of
PF-05280014 (potential trastuzumab biosimilar) and trastuzumab reference product (Herceptin) sourced from the European Union
(trastuzumab-EU) as neoadjuvant treatment for operable human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
METHODS: Patients (N= 226), stratified by primary tumour size and hormone receptor status, were randomised 1:1 to PF-05280014
or trastuzumab-EU (8 mg/kg loading dose; 6 mg/kg thereafter), each with docetaxel and carboplatin, every 3 weeks for six
treatment cycles. Primary endpoint was percentage of patients with trough plasma concentration (Ctrough) >20 μg/ml at Cycle 5
(Cycle 6 predose). Efficacy endpoints included pathological complete response and objective response rate. Non-inferiority of
PF-05280014 to trastuzumab-EU was declared if the lower limit of the 95% confidence interval for the stratified difference between
groups in the percentage of patients with Cycle 5 Ctrough >20 μg/ml was above the prespecified non-inferiority margin of – 12.5%.
RESULTS: For PF-05280014 vs trastuzumab-EU patients, respectively, 92.1% vs 93.3% had Cycle 5 Ctrough >20 μg/ml; the lower limit
of the 95% confidence interval (− 8.02%, 6.49%) for the stratified difference between groups was above the non-inferiority margin
(– 12.5%). Pathological complete response (47.0% vs 50.0%) and central radiology review-assessed objective response (88.1% vs
82.0%) rates were comparable. Incidence of all-causality, grade 3–4 treatment-emergent adverse events was 38.1% vs 45.5%;
antidrug antibody rates were 0% vs 0.89%.
CONCLUSIONS: PF-05280014 demonstrated non-inferior pharmacokinetics and comparable efficacy, safety and immunogenicity to
trastuzumab-EU in patients with operable HER2-positive breast cancer receiving neoadjuvant chemotherapy.
British Journal of Cancer (2018) 119:266–273; https://doi.org/10.1038/s41416-018-0147-1
INTRODUCTION
Trastuzumab is a recombinant humanised immunoglobulin G1
monoclonal antibody that targets human epidermal growth factor
receptor 2 (HER2) and is approved for the treatment of HER2-
overexpressing breast and gastric cancers.1,2 HER2 overexpression
occurs in 15–20% of invasive breast cancers; it is associated with
more-aggressive biological behaviour and, in the absence of
treatment with HER2-targeted therapy, worse clinical outcomes.3–6
The addition of trastuzumab to adjuvant chemotherapy for HER2-
positive (HER2+) early breast cancer or to chemotherapy for
HER2+ metastatic disease reduces the risk for recurrence or disease
progression and prolongs survival as compared with chemotherapy
alone.7–10 When added to neoadjuvant chemotherapy, trastuzumab
improves rates of event-free survival and pathological complete
response (pCR) over chemotherapy alone.11,12
Despite the clinical benefits associated with HER2-directed
therapy, physicians worldwide often encounter barriers to
prescribing trastuzumab, leading to less than optimal treatment
of patients with HER2+ breast cancer.13,14 The availability of
biosimilars may expand access to biologic therapies such as
trastuzumab and provide patients with additional safe and
efficacious treatment options. Biosimilars are biologic drugs
that are highly similar to a licensed (i.e., originator or reference)
biologic product.15–17 To receive regulatory approval, a proposed
biosimilar product must show no clinically meaningful differences
in safety, purity or potency compared with the originator
biologic, based on the totality of the evidence obtained from
comparative assessments of the two products.15–17 Regulatory
agencies recommend a stepwise approach to generating
these data that begins with comprehensive analytical (i.e.,
structural and functional) characterisation followed by non-
clinical testing and culminates with a comparative clinical study
(or studies) to confirm similarity between the proposed biosimilar
and originator product in pharmacokinetics, efficacy, safety and
immunogenicity.15–17
PF-05280014 is under development as a potential biosimilar
of trastuzumab (Herceptin). Comparative non-clinical assessments
of PF-05280014 and trastuzumab reference products marketed
in the European Union (trastuzumab-EU; Herceptin, Roche
Registration GmbH, Grenzach-Wyhlen, Germany) and United States
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(trastuzumab-US; Herceptin, South San Francisco, CA) demonstrated
PF-05280014 has the same primary amino-acid sequence as the
licensed trastuzumab, with similar in vitro functional properties and
in vivo pharmacokinetics, antidrug antibody (ADA) responses and
tolerability.18 Furthermore, two single-dose comparability studies
conducted in healthy male volunteers demonstrated PF-05280014,
trastuzumab-EU and trastuzumab-US have similar pharmacokinetics,
safety and immunogenicity profiles.19,20 An additional, distinct
comparative safety and efficacy study (NCT01989676) is evaluating
PF-05280014 versus trastuzumab-EU, each administered in combi-
nation with paclitaxel, as first-line treatment for patients with HER2+
metastatic breast cancer.21
We report the results of a comparative clinical trial conducted to
compare pharmacokinetics, efficacy, safety and immunogenicity of
PF-05280014 versus trastuzumab-EU, each administered in combi-
nation with docetaxel and carboplatin, as neoadjuvant treatment for
patients with operable HER2+ breast cancer.22 It was hypothesised
that PF-05280014 was non-inferior to trastuzumab-EU, based on
pharmacokinetics data.
METHODS
Study population
Eligible patients were women aged 18 years or older with
histologically confirmed invasive breast cancer that exhibited
HER2 gene amplification by fluorescent in situ hybridisation,
chromogenic in situ hybridisation or dual in situ hybridisation, as
defined by the manufacturer’s kit instruction; or HER2 over-
expression by immunohistochemistry (IHC) categorised as IHC3+;
or HER2 overexpression by IHC categorised as IHC2+ with
fluorescent, chromogenic, or dual in situ hybridisation
confirmation. HER2+ tumour status was determined by the site
at the time of diagnosis, using either a sponsor-approved
assay or two different analytical test methods that were not
considered sponsor-approved but both demonstrated unequivocal
(i.e., IHC3+) results, and confirmed retrospectively by the sponsor-
provided central laboratory. If tumour HER2 status could not be
determined via local testing, it was evaluated by central laboratory
assessment.
Patients with measurable disease (longest diameter ≥ 2.0 cm)
in the breast after diagnostic biopsy and known hormone (oestrogen
and progesterone) receptor status at study entry were included. For
patients with unknown hormone receptor status, oestrogen and
progesterone receptor status testing was performed at
screening, via local or central laboratory assessment. Oestrogen
and progesterone receptor positivity was determined by local site
guidelines based on accepted standards. Baseline tumour assess-
ments were performed within 6 weeks prior to randomisation and
included computed tomography (CT), or magnetic resonance
imaging of the chest if a CT scan could not be performed, and
bilateral mammography or ultrasound of the breast. Patients were
planned to undergo definitive surgical resection of breast tumour
(i.e., lumpectomy or mastectomy with sentinel node biopsy or
axillary lymph node dissection) and neoadjuvant chemotherapy.
Other inclusion criteria included: Eastern Cooperative Oncology
Group performance status 0–1; left ventricular ejection fraction
(LVEF) ≥ 55% as measured by two-dimensional echocardiogram
(ECHO) or multi-gated acquisition scan (MUGA); and normal
laboratory values.
Key exclusion criteria included bilateral breast cancer; inflam-
matory breast cancer; presence of known distant metastases, as
determined by the investigator; prior chemotherapy, endocrine
therapy, biologic therapy, radiation or surgery, except diagnostic
biopsy for primary breast cancer; other concomitant active
malignancy or history of malignancy in the past 5 years, except
treated basal cell carcinoma of the skin or carcinoma in situ of the
cervix; history of documented or current congestive heart failure;
current high-risk uncontrolled arrhythmias; angina pectoris
requiring treatment; clinically significant valvular disease; evidence
of transmural infarction on electrocardiogram; or poorly controlled
hypertension.
Study design, procedures and treatments
This was an international, double-blind, randomised clinical trial
initiated at 67 sites in 10 countries across Europe (EudraCT
registration number 2013-004679-11) and in the United States
(ClinicalTrials.gov identifier NCT02187744).22,23
Patients who satisfied the eligibility criteria were stratified by
primary tumour size (< 5 cm vs ≥ 5 cm) and hormone receptor
status (positive vs negative) and randomised 1:1 to receive
PF-05280014 or trastuzumab-EU (Herceptin), each given in
combination with docetaxel and carboplatin (Fig. 1a). On Day 1
Cycle 1, patients received a loading dose (8 mg/kg, over 90-min
intravenous (IV) infusion) of PF-05280014 or trastuzumab-EU
followed by docetaxel (75 mg/m2; 60-min IV infusion) and
carboplatin (target area under the curve: 6; ≥ 15-min IV infusion).
Subsequent infusions of PF-05280014 or trastuzumab-EU (6 mg/
kg, over 30 to 90 min), docetaxel and carboplatin were
administered every 3 weeks for six treatment cycles. Neoadjuvant
therapy with trastuzumab in combination with docetaxel and
carboplatin has demonstrated efficacy and safety in patients with
HER2+ early breast cancer.24 Furthermore, the trastuzumab
treatment regimen used in this study is consistent with
trastuzumab-EU product labelling and is in line with the National
Comprehensive Cancer Network recommendations on the pre-
ferred preoperative/adjuvant therapy regimens for HER2+ breast
cancer.2,25 Patients who experienced toxicity attributed to PF-
05280014 or trastuzumab-EU were required to temporarily or
permanently discontinue trastuzumab treatment; dose reductions
were not permitted. Granulocyte colony-stimulating factor was
used for prophylactic or therapeutic management of haematolo-
gic toxicities attributed to docetaxel. Reductions in the docetaxel
dose or discontinuation of treatment with docetaxel were
permitted.
Patients had a follow-up assessment, i.e., end of treatment (EOT)
visit, 28 (±7) days after final study drug administration and
underwent definitive surgical resection of their primary breast
tumour within 3–7 weeks following the EOT visit. Systemic therapy
given after resection was not mandated by the protocol and
PF-05280014 or trastuzumab-EU was not provided for treatment in
the adjuvant setting. Patients were not followed for clinical
endpoints after resection.
Objectives and endpoints
The primary objective was to determine whether PF-05280014 is
non-inferior to trastuzumab-EU, based on pharmacokinetics data. The
mechanism of action of trastuzumab is mediated through its binding
to the target receptor HER2, and full receptor saturation is expected
to drive efficacy of trastuzumab.1,2,26 Accordingly, similar trough
plasma concentrations (Ctrough) for PF-05280014 and trastuzumab-EU
would support similar efficacy between treatments. Furthermore,
Ctrough > 20 μg/ml is a therapeutic target threshold concentration for
trastuzumab and has been used to demonstrate noninferiority of
subcutaneous trastuzumab to intravenous trastuzumab in the
neoadjuvant setting.26 Therefore, non-inferiority was assessed by
comparing the percentage of patients with Cycle 5 Ctrough (Cycle 6
predose) > 20 μg/ml (primary endpoint) in the PF-05280014 group
with that in the trastuzumab-EU group. This time point (Cycle 5
Ctrough) was selected because it would be expected to reflect steady
state drug concentration based on population predicted pharmaco-
kinetic exposure values for the approved 3-weekly dosing regimen
used in this study.2
Secondary objectives were to evaluate the efficacy, safety,
immunogenicity and other pharmacokinetic measures of
PF-05280014 and trastuzumab-EU. Efficacy was measured by the
percentage of patients with pCR, defined as the absence of
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invasive neoplastic cells in the breast and lymph nodes following
surgery after treatment completion (remaining ductal carcinoma
in situ was accepted),26 and objective response rate (ORR), defined
as the percentage of patients who had complete or partial
response at Cycle 6/EOT. Safety was characterised by the type,
incidence, severity, timing, seriousness and relatedness of adverse
events (AEs) to study drug, including cardiotoxicity, signs and
symptoms of anaphylaxis, infusion-related reactions and labora-
tory abnormalities. Immunogenicity was measured by the
incidence of ADAs, including neutralising antibodies (NAbs).
Pharmacokinetics was further assessed by measuring Ctrough at
Cycles 1 (Cycle 2 predose), 3 (Cycle 4 predose) and 4 (Cycle 5
predose), as well as Cmax (maximum drug concentration, 1 h post
dose) at Cycles 1 and 5.
Assessments
Blood samples for determining PF-05280014 or trastuzumab-EU
serum concentrations were collected predose (–2.5 h to –5min
prior to infusion) on Day 1 of Cycles 1, 2, 4, 5 and 6, and at 1-h post
dose on Day 1 of Cycles 1 and 5. Samples were analysed using a
validated enzyme-linked immunosorbent assay with a lower limit
of quantification of 0.500 µg/ml. Pathological response status was
determined by an investigator-designated qualified pathologist.
Tumour assessments were performed at screening, end of Cycle 3,
EOT and as clinically needed. Objective response status was
determined by a central radiology laboratory and by the
investigators using Response Evaluation Criteria in Solid Tumours,
version 1.1. Central radiology assessments were used to calculate
ORR at Cycle 6/EOT.
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Fig. 1 Overall study design and disposition of patients. a Study design and b patient disposition. aOn Day 1 Cycle 1, patients received a
loading dose (8 mg/kg) of PF-05280014 or trastuzumab-EU infused over 90min followed by docetaxel (75 mg/m2; 60-min intravenous
infusion) and carboplatin (target AUC: 6; ≥ 15-min intravenous infusion). Subsequent infusions of PF-05280014 or trastuzumab-EU (6mg/kg,
over 30 to 90min), docetaxel and carboplatin were administered every 3 weeks for a total of six treatment cycles. bBlood samples were
collected predose (−2.5 h to −5min prior to infusion) on Day 1 of Cycles 1, 2, 4, 5 and 6, and at 1-h post dose on Day 1 of Cycles 1 and 5 for
determination of PF-05280014 or trastuzumab-EU serum concentrations. cThe intent-to-treat population consisted of all patients randomised
to PF-05280014 or trastuzumab-EU. dThe safety population comprised all patients who received at least one dose of study drug. ePatients in
the PF-05280014 group were excluded from the per protocol population for the following reasons: Cycle 5 trough sample taken outside
protocol-specified window (n= 6, 46.2%), fewer than six cycles of trastuzumab (n= 5, 38.5%), no Cycle 5 trough pharmacokinetic sample
(n= 2, 15.4%), and trastuzumab treatment delay > 1 week (n= 1, 7.7%). A patient may have met multiple criteria for exclusion and may have
been counted more than once. fPatients in the trastuzumab-EU group were excluded from the per protocol population for the following
reasons: Cycle 5 trough sample taken outside protocol-specified window (n= 13, 56.5%), fewer than six cycles of trastuzumab (n= 5, 21.7%),
trastuzumab treatment delay > 1 week (n= 3, 13.0%), Cycle 5 trough sample taken post dose (n= 1, 4.3%), no lesion > 2 cm in breast (n= 1,
4.3%), and missing HER2 sample (n= 1, 4.3%). A patient may have met multiple criteria for exclusion and may have been counted more than
once. gThe per protocol population consisted of all randomised patients who received six cycles of PF-05280014 or trastuzumab-EU and had
no temporary delays in treatment lasting > 1 week or other significant protocol deviations. AUC= area under the curve; HER2= human
epidermal growth factor receptor 2; trastuzumab-EU= licensed trastuzumab sourced from the European Union
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AEs were monitored continuously from the time the patient
received at least one dose of study drug through the last patient
visit. The severity of AEs was graded in accordance with the
National Cancer Institute Common Terminology Criteria for
Adverse Events, version 4.03. Cardiac monitoring (MUGA scan or
ECHO) was performed at screening, end of Cycle 3, EOT visit and
as clinically indicated. Serum samples for detecting ADAs and
NAbs were collected on Day 1 (predose) of Cycles 1, 2, 4 and 6
(Fig. 1a), and during the EOT visit. Samples were tested for ADAs
following a tiered approach of screening, confirmation and titre.
Samples were first analysed using a validated electrochemilumi-
nescent immunoassay specific to PF-05280014 or trastuzumab-EU.
ADA-positive samples were then analysed for cross-reactivity
using the alternate assay. Confirmed ADA-positive samples were
tested for NAb using a validated electrochemiluminescent
immunoassay specific to the monoclonal antibody administered;
NAb-positive samples were then analysed for cross-reactivity
using the alternate assay.
Statistical methods
This study tested the hypothesis that the percentage of patients
exhibiting Cycle 5 Ctrough (Cycle 6 predose) > 20 μg/ml in the
PF-05280014 group was non-inferior to that in the trastuzumab-
EU group, using a margin of – 12.5%. This margin was selected
based on clinical considerations rather than statistical
considerations (e.g., a meta-analysis of previous data) as there is
little previous evidence in the neoadjuvant setting outside of the
HannaH trial, which evaluated non-inferiority of subcutaneous
trastuzumab to intravenous trastuzumab based on pCR rate
and using a margin of − 12.5%.26 A minimum of 188 patients
(n= 94/arm) was required to provide 85% power to test for
non-inferiority in the primary analysis. Considering a possible 15%
attrition rate, a total sample size of ~ 220 patients (n= 110/arm)
was planned to ensure the required minimum number of patients
for the non-inferiority analysis.
Differences between groups in the percentage of patients with
Cycle 5 Ctrough (Cycle 6 predose) > 20 μg/ml, the percentage of
patients who had pCR and the ORR were estimated, along with
corresponding 95% confidence intervals, using the normal
approximation to the binomial distribution and adjusting for
randomisation strata. If the lower limit of the CI for the primary
endpoint was above – 12.5%, the null hypothesis was rejected and
PF-05280014 was considered non-inferior to trastuzumab-EU.
Cycle 5 Ctrough (Cycle 6 predose) values were log-transformed
and the geometric ratio (PF-05280014 to trastuzumab-EU) of the
means and corresponding 95% CI were also estimated (secondary
pharmacokinetics endpoint).
Pharmacokinetics and efficacy analyses were performed in the
per protocol population, defined as all randomised patients who
received six cycles of PF-05280014 or trastuzumab-EU and had no
temporary delays in treatment that lasted > 1 week and no other
significant protocol deviations. Sensitivity analyses of the primary
and efficacy endpoints were performed in the intent-to-treat
population (i.e., all randomised patients). Safety analyses, includ-
ing AE, ADA and NAb analyses, were performed using the safety
population (i.e., all patients who received at least one dose of
study drug).
RESULTS
Patient disposition, demographics and baseline characteristics
A total of 226 patients were randomised to PF-05280014 (n= 114)
or trastuzumab-EU (n= 112) and were included in the intent-to-
treat population. Of these, one patient was randomised to but did
not receive treatment with PF-05280014; the remaining 225
patients received study treatment as assigned and were included
in the safety population (Fig. 1b). Of the 226 randomised patients,
190 (PF-05280014, n= 101; trastuzumab-EU, n= 89) met the
requirements for the per protocol population, and 36
(PF-05280014, n= 13; trastuzumab-EU, n= 23) were excluded for
one or more of the following reasons, which were determined
prior to breaking the blind (Fig. 1b): Cycle 5 trough sample taken
outside the protocol-specified window, Cycle 5 trough sample
taken post dose, fewer than six cycles of trastuzumab treatment,
no Cycle 5 trough pharmacokinetics sample, no lesion > 2 cm in
breast, missing HER2 sample and/or trastuzumab treatment delay
> 1 week. Patient demographics and other baseline characteristics
for the intent-to-treat population were comparable between
treatment groups (Table 1).
Pharmacokinetic analyses
In an analysis of the primary endpoint using the per protocol
population, 93 (92.1%) patients treated with PF-05280014 and 83
(93.3%) patients treated with trastuzumab-EU exhibited Cycle 5
Ctrough (Cycle 6 predose) >20 μg/ml (Table 2). The stratified
estimated difference between PF-05280014 and trastuzumab-EU
was – 0.76%, and the lower limit of the 95% CI (– 8.02%, 6.49%)
was above the non-inferiority margin of – 12.5%. In an analysis
of secondary pharmacokinetics endpoints using the per
protocol population, the geometric mean Ctrough at Cycle 5 was
34.59 and 34.56 µg/ml for PF-05280014 and trastuzumab-EU,
respectively; the PF-05280014 to trastuzumab-EU ratio was
100.06% (95% CI: 81.5%, 122.9%). In addition, at each study cycle,
trastuzumab serum concentrations appeared comparable between
PF-05280014 and trastuzumab-EU (Supplementary Tables S1
and S2).
Efficacy analyses
Pathologic response and overall tumour response assessments for
the per protocol population are summarised in Table 3. Of the
patients in the PF-05280014 (n= 100) and trastuzumab-EU
(n= 86) groups who had surgery, 47.0% (95% CI: 36.9%, 57.2%)
Table 1. Baseline demographics (intent-to-treat population)a
PF-05280014
(n= 114)
Trastuzumab-EU
(n= 112)
Total
(N= 226)
Age, mean (±SD), years 54.0 (11.9) 51.2 (12.7) 52.6 (12.3)
Race, n (%)
White 112 (98.2) 109 (97.3) 221 (97.8)
Black 1 (0.9) 0 1 (0.4)
Asian 1 (0.9) 3 (2.7) 4 (1.8)
Ethnicity, n (%)
Hispanic/Latino 0 1 (0.9) 1 (0.4)
Not Hispanic/Latino 114 (100.0) 111 (99.1) 225 (99.6)
Mean body mass
index (±SD), kg/m2
28.2 (5.9) 27.7 (6.2) 27.9 (6.1)
Primary tumour size, n (%)
<5 cm 89 (78.1) 89 (79.5) 178 (78.8)
≥5 cm 25 (21.9) 23 (20.5) 48 (21.2)
Oestrogen receptor status, n (%)
Positive 58 (50.9) 54 (48.2) 112 (49.6)
Negative 56 (49.1) 58 (51.8) 114 (50.4)
Progesterone receptor status, n (%)
Positive 41 (36.0) 40 (35.7) 81 (35.8)
Negative 73 (64.0) 72 (64.3) 145 (64.2)
aBaseline was defined as the value recorded at Day 1 Cycle 1. If this value
was missing, the value recorded at screening was used. Trastuzumab-EU=
licensed trastuzumab sourced from the European Union; SD= standard
deviation
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and 50.0% (95% CI: 39.0%, 61.0%), respectively, had a pCR; the
stratified estimated difference between groups was – 2.81%
(95% CI: – 16.58%, 10.96%). The ORR at Cycle 6/EOT was 88.1%
(95% CI: 80.2%, 93.7%) for PF-05280014 and 82.0% (95% CI: 72.5%,
89.4%) for trastuzumab-EU, based on central radiology assess-
ments; the stratified estimated difference between groups was
5.96% (95% CI: –4.01%, 15.94%).
Safety
Among patients included in the safety population (PF-05280014,
n= 113; trastuzumab-EU, n= 112), 109 (96.5%) in the
PF-05280014 group and 109 (97.3%) in the trastuzumab-EU group
received six cycles of trastuzumab. Six patients each in the
PF-05280014 (5.3%) and trastuzumab-EU (5.4%) groups had a
delay in trastuzumab treatment. Eight (7.1%) patients
administered PF-05280014 and 7 (6.3%) who received
trastuzumab-EU had an interrupted trastuzumab infusion.
The majority of all patients experienced at least one treatment-
emergent AE (TEAE) owing to any cause, with a total of 569 events
reported by 109 (96.5%) patients in the PF-05280014 group and
511 events reported by 106 (94.6%) patients in the trastuzumab-
EU group (Table 4). The incidence of TEAEs and serious TEAEs was
comparable between groups. The TEAEs most frequently reported
by patients (n (%)) in the PF-05280014 and trastuzumab-EU
groups, respectively, were alopecia (72 (63.7%) and 69 (61.6%)),
anaemia (56 (49.6%) and 51 (45.5%)) and neutropaenia (38 (33.6%)
and 41 (36.6%)). Grade 3–4 TEAEs were reported in 43 (38.1%) and
51 (45.5%) patients in the PF-05280014 and trastuzumab-EU
groups, respectively. Seven (6.2%) patients treated with
PF-05280014 experienced seven serious AEs (SAEs; febrile
neutropaenia, neutropaenia, pancytopenia, proctitis, device-
related sepsis, injection-site abscess and increased blood creati-
nine); six (5.4%) patients treated with trastuzumab-EU experienced
10 SAEs (anaemia, febrile neutropaenia (n= 2), neutropaenia
(two SAEs, n= 1), gastrointestinal infection, tooth infection, hip
fracture, dehydration and hypokalaemia).
No TEAEs indicative of infusion-related reactions were
reported in the PF-05280014 group; two (1.8%) patients in the
trastuzumab-EU group experienced non-serious events of pyrexia
and tachypnea. Four (3.5%) and three (2.7%) patients in the
PF-05280014 and trastuzumab-EU groups, respectively,
permanently discontinued from any treatment due to AEs during
the treatment period. One patient in the PF-05280014 group died
due to a treatment-related SAE of pancytopenia; no other patients
died during the study. No TEAEs of congestive heart failure or
clinically significant LVEF abnormalities were reported by patients
in either treatment group. There were no notable differences
between the treatment groups in mean LVEF results (Supplemen-
tary Table S3). One (0.88%) and 10 (8.93%) patients in the
PF-05280014 and trastuzumab-EU groups, respectively, had a
decline in LVEF of ≥ 10% from baseline. However, no patient in
either group had LVEF < 53% at any time point measured.
Furthermore, no individual abnormalities or shifts in laboratory
values were considered clinically relevant.
Immunogenicity
No patients in the PF-05280014 group and one (0.89%) patient in
the trastuzumab-EU group had positive ADA titres (Table 5). The
single positive ADA titre of 2.39 was recorded at predose Cycle 1.
This patient also recorded a cross-reactivity ADA assay titre of 2.58,
but was negative in all subsequent ADA tests and also tested
negative for NAbs.
DISCUSSION
The primary objective of this comparative clinical trial in patients
with operable HER2+ breast cancer was to determine whether
neoadjuvant treatment with PF-05280014, a potential trastuzu-
mab biosimilar, was non-inferior to trastuzumab-EU, based on
pharmacokinetic data. This objective was met; the study demon-
strated non-inferiority for PF-05280014 versus trastuzumab-EU in
the percentage of patients with Cycle 5 Ctrough (Cycle 6 predose)
> 20 μg/ml. Furthermore, results from an analysis of secondary
endpoints demonstrated comparable pharmacokinetic profiles for
PF-05280014 and trastuzumab-EU.
PF-05280014 and trastuzumab-EU also had comparable efficacy
profiles, based on measures of tumour control, with no notable
difference between treatment groups (PF-05280014 vs trastuzu-
mab-EU, respectively) in pCR rate (47.0% vs 50.0%) or ORR (88.1%
vs 82.0%). Importantly, pCR results were consistent with published
data for trastuzumab administered in combination with neoadju-
vant chemotherapy.27,28 Furthermore, both pCR and ORR were
comparable to rates reported for other proposed trastuzumab
biosimilars in development and evaluated in the neoadjuvant
setting.29,30
Both treatments were generally well tolerated, with few patients
discontinuing from any treatment due to AEs. There was no
clinically significant imbalance between groups in TEAEs, serious
TEAEs or other observed safety parameters. PF-05280014 and
trastuzumab-EU also had comparable immunogenicity profiles,
wherein no patients in the PF-05280014 group and one patient in
the trastuzumab-EU group tested positive for ADAs. These data
are consistent with previous studies demonstrating a low
immunogenic potential for trastuzumab.19,31 As part of a stepwise
comparison exercise to demonstrate biosimilarity, these findings
build on those of previous analytical and non-clinical studies and
two single-dose studies in healthy volunteers.18–20
The current study applied a non-inferiority design to compare
PF-05280014 with trastuzumab-EU. Generally, biosimilarity studies
use an equivalence design to show the biosimilar is neither
superior nor inferior to the originator product and vice
versa.16,17,32 However, in some cases, a non-inferiority design
may be adequate to demonstrate that there are no clinically
meaningful differences between the proposed biosimilar product
and originator biologic.16 This study may be limited by its use of a
margin for non-inferiority of the clinical endpoint pCR to establish
non-inferiority using a primary endpoint based on pharmacoki-
netics data. However, a non-inferiority margin based on clinical
considerations rather than statistical considerations is supported
Table 2. Primary pharmacokinetics analysis of patients reporting Cycle 5 Ctrough
a >20 μg/ml (per protocol population)
PF-05280014 (n= 101) Trastuzumab-EU (n= 89)
Patients with Cycle 5 Ctrough
a > 20 μg/ml, % (95% CI) 92.1 (85.0, 96.5) 93.3 (85.9, 97.5)
Stratified difference between PF-05280014 and trastuzumab-EUb −0.76
Standard error for the difference 3.70
95% CI (stratified) for the difference −8.02, 6.49
aCycle 6 predose. bStratified analysis was based on the normal approximation to the binomial distribution, adjusting for randomisation strata (primary tumour
size < 5 cm vs ≥5 cm; oestrogen receptor-positive vs oestrogen receptor-negative; and progesterone receptor-positive vs progesterone receptor-negative).
CI= confidence interval; Ctrough= trough plasma concentration; trastuzumab-EU= licensed trastuzumab sourced from the European Union
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by a lack of previous evidence in the neoadjuvant setting outside
of the HannaH trial.26 In addition, this study was not powered to
evaluate non-inferiority in pCR or ORR, which may limit
interpretation of clinical efficacy findings. However, a comparative
study of PF-05280014 versus trastuzumab-EU, each in combina-
tion with paclitaxel, as first-line treatment in patients with HER2+
metastatic breast cancer used an equivalence design, and
preliminary results demonstrated that this trial met its primary
endpoint of similarity in ORR.33
The strengths of the current trial include its randomised,
double-blind design, homogeneous patient population and use of
clinical endpoints that measure activity (e.g., tumour response).
The most frequently published definition of pCR (absence of
invasive neoplastic cells in breast and lymph nodes following
Table 3. Pathological response and overall tumour response
assessments (per protocol population)
PF-05280014
(n= 101)
Trastuzumab-EU
(n= 89)
Pathological response assessment
Response category, n (%)
pCR 47 (46.5) 43 (48.3)
pPR 51 (50.5) 40 (44.9)
No pathological response 2 (2.0) 3 (3.4)
Not donea 1 (1.0) 3 (3.4)
Patients who had surgery
n (%) 100 (99.0) 86 (96.6)
Patients with pCR,b n (%) 47 (47.0) 43 (50.0)
95% CI 36.9, 57.2 39.0, 61.0
Stratified difference in pCR
between PF-05280014 and
trastuzumab-EUc
−2.81
Standard error for the
difference
7.03
95% CI (stratified) for the
difference
−16.58, 10.96
Overall response assessment (per central radiology review)
Overall response category at Cycle 6/EOT, n (%)
Complete response 3 (3.0) 0
Partial response 86 (85.1) 73 (82.0)
Stable disease 7 (6.9) 4 (4.5)
Progressive disease 2 (2.0) 1 (1.1)
Non-evaluable 1 (1.0) 6 (6.7)
Non-complete response/
non-progressive disease
1 (1.0) 3 (3.4)
Missing 1 (1.0) 2 (2.2)
ORRd
n (%) 89 (88.1) 73 (82.0)
95% CI 80.2, 93.7 72.5, 89.4
Stratified difference in ORR
between PF-05280014 and
trastuzumab-EUc
5.96
Standard error for the
difference
5.09
95% CI (stratified) for the
difference
−4.01, 15.94
aPathology data were not recorded or response was not assessed for the
following reasons: completed the study but had no surgery (PF-05280014,
n= 1; trastuzumab-EU, n= 1) or completed treatment but lost to follow-up
prior to surgery (trastuzumab-EU, n= 2). bThe denominators for percen-
tages of patients with pCR included only patients who had surgery.
cStratified analysis was based on the normal approximation to the binomial
distribution, adjusting for randomisation strata (primary tumour size
< 5 cm vs ≥ 5 cm; oestrogen receptor-positive vs oestrogen receptor-
negative; and progesterone receptor-positive vs progesterone receptor-
negative). dORR was defined as the percentage of patients within each
treatment group who achieved complete response or partial response by
Cycle 6/EOT, in accordance with Response Evaluation Criteria in Solid
Tumours, version 1.1. CI= confidence interval; EOT= end of treatment;
ORR= objective response rate; pCR= pathological complete response;
pPR= pathological partial response; trastuzumab-EU= licensed
trastuzumab sourced from the European Union
Table 4. All-causality, treatment-emergent adverse events
(safety population)a
PF-05280014
(n= 113)
Trastuzumab-EU
(n= 112)
Number of AEs 569 511
Patients with event, n (%)
AEs 109 (96.5) 106 (94.6)
SAEsb 7 (6.2) 6 (5.4)
Grade 3 or 4 AEs 43 (38.1) 51 (45.5)
Grade 5 AEs 1 (0.9) 0
Discontinued study due to AEs 1 (0.9) 3 (2.7)
Discontinued from any
treatmentc due to AEs
4 (3.5) 3 (2.7)
Dose reduced or temporarily
discontinued for any
treatmentc due to AEs
37 (32.7) 30 (26.8)
aIncludes data up to 50 days after the last dose of study drug. Patients were
counted only once per treatment in each row, except for the Number of
AEs. bAs determined by investigator. cTrastuzumab (PF-05280014 or
trastuzumab-EU), docetaxel or carboplatin. AE= adverse event; SAE=
serious adverse event; trastuzumab-EU= licensed trastuzumab sourced
from the European Union
Table 5. Incidence of ADAs by visit and overall (safety population)a
Visit ADA status PF-05280014 Trastuzumab-EU
Cycle 1 Patients assessed, n 113 112
Negative < 1.00, n (%) 113 (100.00) 110 (98.21)
Positive ≥ 1.00, n (%) 0 1 (0.89)
Not analysed, n (%) 0 1 (0.89)
Cycle 2 Patients assessed, n 111 112
Negative < 1.00, n (%) 111 (100.00) 112 (100.00)
Positive ≥ 1.00, n (%) 0 0
Cycle 4 Patients assessed, n 108 109
Negative < 1.00, n (%) 108 (100.00) 109 (100.00)
Positive ≥ 1.00, n (%) 0 0
Cycle 6 Patients assessed, n 108 108
Negative < 1.00, n (%) 108 (100.00) 108 (100.00)
Positive ≥ 1.00, n (%) 0 0
Overall Patients assessed, n 113 112
Negative < 1.00, n (%) 113 (100.00) 111 (99.11)
Positive ≥ 1.00, n (%) 0 1 (0.89)
aPercentages are based on the number of patients assessed at each visit.
The unit of ADA titre was endpoint titre. Only predose assessments are
summarised. ADA= antidrug antibody; trastuzumab-EU= licensed trastu-
zumab sourced from the European Union
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neoadjuvant therapy) was used, consistent with previous studies
of trastuzumab administered concurrently with chemotherapy in
the neoadjuvant setting.11,12,26 Furthermore, calculation of ORR for
efficacy analysis was based on independent central radiologic
review of tumour assessments. Finally, neoadjuvant use of
trastuzumab is not currently approved by the US Food and Drug
Administration1; however, it is authorised by the European
Medicines Agency and is well known and used in clinical practice
in Europe and the United States.2,25,34,35 Therefore, the finding of
comparable efficacy in terms of pCR and ORR in this setting may
be reassuring for patients and clinicians.
In conclusion, neoadjuvant treatment with the potential
biosimilar PF-05280014 administered in combination with
docetaxel and carboplatin demonstrated non-inferiority in phar-
macokinetics and comparability in efficacy, safety and immuno-
genicity when compared with trastuzumab-EU in combination
with docetaxel and carboplatin in patients with operable
HER2+ breast cancer. These results support similarity of
PF-05280014 to trastuzumab-EU as part of the stepwise
comparison exercise for demonstrating biosimilarity. As a
potential biosimilar of trastuzumab, PF-05280014 could broaden
the number of treatment options for patients with HER2+ breast
cancer and allow greater use of anti-HER2 therapy across clinical
settings.
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